Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for inoperable bile duct cancer: targeted therapies aim to shrink tumors

NCT ID NCT06313203

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard chemotherapy. The goal is to see if these combinations can shrink tumors enough to allow surgery or help patients live longer. About 39 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Floxuridine (via hepatic artery infusion) and Yttrium-90 radioactive particles (via selective internal radiation therapy)
What this could lead to
If successful, this could offer a way to shrink inoperable bile duct tumors enough for surgery, potentially improving survival and giving more patients a chance at a cure.
What could go wrong
This is a small, early-phase trial (39 people) without randomization, so results may not apply broadly. Both treatments have risks like liver damage or infection, and the floxuridine arm requires frequent hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 39 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jan 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Intra-hepatic cholangiocarcinoma. Diagnosis confirmed by biopsy, cytology or previous resection. 2. Not amenable for upfront resection. Defined as: 1. A tumour that is technically not resectable with R0 margins (i.e. where resection will not yield an FLR of sufficient size and function) without reconstruction of portal or liver vein, or artery. 2. Any multifocality (more than one tumour) irrespective of distance between assumed primary and other lesions 3. Recurrent tumour following resection 4. Radiologically or cytology-proven malignant regional lymph nodes 3. Disease confined to the liver or associated with limited, resectable porta hepatis lymph node metastases 4. Radiologically measurable disease with at least one lesion \> 2 cm in greatest diameter 5. Physical performance score WHO/ECOG stage 0/1 6. Age \> 18 years 7. Assumed ability to tolerate at least one full cycle of GemOx 8. For eligibility to HAI-FUDR/DEX treatment, patients must be willing and able to go to Oslo every fortnight 9. Women of childbearing age and potential must be willing to use highly effective contraception during the study and for a period after the study, as defined in this protocol. Male patients or male patients who have female partners of childbearing age and potential must be willing to use highly effective contraception during the study and for a period after the study, as defined in this protocol. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Exclusion Criteria: 1. Any non-liver malignant deposit (except for resectable, hilar lymph nodes) 2. Serum bilirubin, creatinine or INR outside of normal range 3. Haemoglobin \< 7 g/dL and thrombocytes \< 75 × 109/L 4. Liver failure (if cirrhosis, Child-Pugh B or C) 5. Clinical evidence of portal hypertension (non-surgically related ascites, gastro-oesophageal varices, portal vein thrombosis) 6. History of peripheral neuropathy 7. More than 70 % of liver consisting of tumour 8. History of other malignancy past three years except localized/early stage cancer that has been adequately resected. 9. Pregnant or lactating women 10. Expected life expectancy less than three months. 11. Inability to comply with study routines or follow-up procedures 12. Inability to read and comprehend Norwegian 13. Arterial anatomy unsuited for SIRT or HAI, respectively 14. Any reason why, in the view of the investigators, the patient should not be included

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy effect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Oslo University Hospital

    RECRUITING

    Oslo, Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.